Crossmark

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals

Published Online: 2025-09-25

Authors

Trevaskis, James L. https://orcid.org/0000-0002-5356-6118
Parkes, David G.

Young, Andrew A.
License Information

Text and Data Mining valid from 2025-09-25

Version of Record valid from 2025-09-25
More Information

Article History

First Online: 25 September 2025

Competing interests

: All authors are former employees of Amylin Pharmaceuticals Inc. J.L.T is an employee and shareholder of Eli Lilly and Co. A.A.Y is an employee of i20 Therapeutics. D.G.P. receives consulting fees from Epirium, Prolynx, Neurocrine, Pioneering Medicine and UCSD.

Document is current